Iruplinalkib

Iruplinalkib (WX-0593) is an orally active and selective ALK/ROS1 inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC50 between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter MATE1, MATE2K, P-gp and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer[1][2].

Product Specifications

CAS Number

[1854943-32-0]

Product Name Alternative

WX-0593

UNSPSC

12352005

Target

Akt; Anaplastic lymphoma kinase (ALK) ; BCRP; ERK; ROS Kinase; STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iruplinalkib.html

Purity

99.62

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=P(C)(C)C1=C(NC2=NC(NC3=CC=C(N4CCC5(CCN(CC5)C)CC4)C=C3OC)=NC=C2Cl)C=CC=C1

Molecular Formula

C29H38ClN6O2P

Molecular Weight

569.08

References & Citations

[1]Shi Y, et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7 (1) :25. |[2]Yang Y, et al. Iruplinalkib (WX 0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. Invest New Drugs. 2023 Apr;41 (2) :254-266.